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ABSTRACT
Background and Objectives: Gender-related differences in health care utilization for atrial 
fibrillation (AF) are increasingly recognized. However, large cohort data for examining 
gender-related differences in AF are lacking in Asian populations.
Methods: The Registry for Comparison Study of Drugs for Symptom Control and 
Complication Prevention of AF (CODE-AF Registry) is a prospective observational 
cohort-study that enrolled participants at 10 tertiary hospitals in South Korea. Baseline 
characteristics retrieved from the CODE-AF Registry were analyzed.
Results: A total of 6,274 patients were recruited (mean age 67±11 years, mean CHA2DS2-
VASc score 2.7±1.7, 63% male, 65% paroxysmal AF) from June 2016 to April 2017. Women 
underwent less electric cardioversion (12.3% vs. 19.6%, p<0.001), less radiofrequency 
ablation (12.4% vs. 17.9%, p<0.001), and less antiarrhythmic drug therapy (44.7% vs. 49.5%, 
p<0.001), despite having more severe symptoms (symptom class III or IV, 45.8% vs. 37.5%, 
p<0.001). Among patients with a CHA2DS2-VA score of 2 or more, a slightly higher proportion 
of women were taking oral anticoagulants than men (85.7% vs. 81.9%, p=0.002), and non-
vitamin K antagonist oral anticoagulant (NOAC) use was more prevalent in women than men 
(70.4% vs. 62.3%, p<0.001). Insufficient NOAC dosing was very common, more so in women 
than men (61.5% vs. 56.3%, p<0.001).
Conclusions: Female patients with AF were treated more conservatively and rhythm control 
strategies were used less frequently than in males, even though the female patients with AF 
had more severe symptoms. While insufficient NOAC dosing was common in both sex, it was 
significantly more frequent in women.
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INTRODUCTION
A topic of current interest is whether gender-related differences exist in the use of health 
care resources for managing atrial fibrillation (AF), and whether/how these differences 
affect clinical outcomes.1-5) Despite many advances in rhythm control methods, including 
radiofrequency catheter ablation, women are less likely to be selected for rhythm control 
strategies based on analyses of data from Europe and North America.3)6)7) Although AF 
is less prevalent in women than in men, women with AF have a higher risk of stroke and 
death than men. The risk of developing AF is about 2 times higher in men than in women.8) 
However, because women live longer than men and the prevalence of AF increases with age, 
there are more women than men with AF.1) In addition, female sex has been shown to be an 
independent risk factor for AF-related stroke.9)10) Therefore, improving stroke prevention in 
women with AF is important for reducing the public health burden of AF. However, it has 
been reported that women are less likely to undergo anticoagulation, mainly in the warfarin 
era.5) Non-vitamin K antagonist oral anticoagulants (NOACs) such as the direct thrombin 
inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban are now 
approved and widely used for stroke prevention in patients with AF.11-14) However, it is unknown 
whether there are any gender-related differences in anticoagulation, even in the NOAC era. 
Moreover, little data from Asian women are available to address this question. Therefore, we 
investigated whether there are sex-specific differences in the management of AF using a large 
Korean cohort and compared our findings to those of studies in Western countries.
METHODS
Study population
The Registry for Comparison Study of Drugs for Symptom Control and Complication 
Prevention of AF (CODE-AF Registry) is a prospective observational cohort study whose 
goal was to compare the use of different drugs for rate control, rhythm control, and 
anticoagulation therapy for stroke prevention in patients with AF. The study enrolled 
participants in 10 tertiary hospitals encompassing all geographical regions of South Korea. 
The registry was designed and coordinated by the Korea Heart Rhythm Society, which 
provides support to related committees, national coordinators, and participating centers. 
Data are entered in a common electronic database that limits inconsistencies and errors and 
provides online help for key variables. Each center has access to its own data and data from 
all other participating centers. The number of patients enrolled from each center is shown 
in previous publication.15) A follow-up visit was scheduled every 6 months, either through 
personal interview or telephone contact. The study was approved by the ethics committee 
of each center and all patients provided informed consent for their inclusion. This study is 
registered at www.ClinicalTrials.gov (NCT02786095).
Definition of variables
Nonvalvular AF was defined as AF without moderate or severe rheumatic mitral stenosis and 
without a mechanical mitral valve. Paroxysmal AF was defined as AF that was terminated 
before 7 days, with or without medical intervention. Persistent AF was any AF that lasted 
longer than 7 days continuously. AF was classified as paroxysmal if it terminated within 7 
days and persistent if it lasted longer than 7 days.16) Congestive heart failure, hypertension, 
age >75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 
>65, female (CHA2DS2-VASc) and hypertension, abnormal renal/liver function; serum 
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creatinine ≥2.3 mg/dL or bilirubin >2×upper limit of normal, in association with aspartate 
aminotransferase/alanine aminotransferase/alkaline phosphatase >3×upper limit of normal, 
stroke, bleeding history or predisposition, labile international normalized ratio, elderly, 
drugs/alcohol concomitantly (HAS-BLED) scores were calculated for all patients with 
nonvalvular AF.17)
Statistical analysis
Continuous variables that were normally distributed are reported as means±standard 
deviations and were compared using Student's t-test. Categorical variables are reported 
as counts (percentages) and were compared using the χ2 test or Fisher's exact test if any 
expected cell count was less than 5. Logistic regression models were constructed to identify 
significant factors that influence anticoagulation decisions. The R package (version 3.2.4; 
R Foundation for Statistical Computing, Vienna, Austria) was used to perform all statistical 
evaluations. A 2 tailed p value <0.05 was considered statistically significant.
RESULTS
Baseline characteristics
The CODE-AF study commenced recruitment in June 2016. A total of 6,274 patients were 
recruited (mean age 67±11 years, mean CHA2DS2-VASc score 2.7±1.7, 63% male, 65% 
paroxysmal AF) from June 2016 to April 2017. The patient baseline characteristics are 
shown in Table 1. Compared to male patients, female patients were older and had a higher 
prevalence of hypertension and dyslipidemia. Female patients also had more severe AF-
related symptoms than male patients (European Heart Rhythm Association [EHRA] III or IV: 
45.8% vs. 37.5%, p<0.001), and received more permanent pacemakers.
Body mass index, diabetes, prior valve surgery, prior stroke, chronic kidney disease, and prior 
bleeding event were not significantly different between males and females.
Male patients were more likely to be smokers, have higher alcohol intake, and had a higher 
prevalence of myocardial infarction and cancer. Female patients were more likely to have a 
CHA2DS2-VASc score ≥2 than male patients.
To analyze anticoagulation status according to the recent European guideline, CHA2DS2-VA 
scores were calculated (without the point for the sex category). Female patients were more 
likely to have a CHA2DS2-VA score ≥2 (69.3% vs. 60.2%, p<0.001). CHADS2 ≥2 was also more 
frequent in females (55.3% vs. 50.4%, p<0.001). There was no significant difference in HAS-
BLED between men and women.
Rhythm and rate control therapy
Table 2 showed the distribution of rhythm and rate control methods in detail. In women, the 
attempt of any rhythm control modality was significantly less frequent than in men. Women 
underwent electric cardioversion less frequently, radiofrequency ablation less frequently, 
and used anti-arrhythmic drug therapy less frequently. Analysis of individual antiarrhythmic 
drugs revealed that amiodarone was the only drug that was used significantly less often 
in women than men. The use of beta blockers and calcium channel blockers was similar 
between both sexes. However, digitalis was used more frequently in women.
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Table 1. Baseline characteristics of the subjects according to gender
Female (n=2,308) Male (n=3,966) p
Age (years) 70.1±9.8 65.7±11.1 <0.001
Height (cm) 155.3±6.2 169.1±6.2 <0.001
Weight (kg) 59.2±9.6 70.7±10.7 <0.001
Body mass index (kg/m2) 24.5±3.7 24.7±3.1 0.174
Current smoking 19 (0.8) 524 (13.2) <0.001
Alcohol intake 136 (6.0) 1,366 (42.0) <0.001
Paroxysmal AF 1,546 (67.5) 2,553 (64.5) 0.072
Symptomatic AF (EHRA 3 or 4) 1,049 (45.8) 1,483 (37.5) <0.001
CHA2DS2-VASc score 3.2±1.3 1.9±1.3 <0.001
CHA2DS2-VASc score ≥2 2,066 (90.1) 2,382 (60.2) <0.001
CHADS2 score 1.8±1.2 1.7±1.2 <0.001
CHADS2 score ≥2 1,268 (55.3) 1,993 (50.4) <0.001
CHA2DS2-VA score* 2.2±1.3 1.9±1.3 <0.001
CHA2DS2-VA score ≥2* 1,589 (69.3) 2,382 (60.2) <0.001
HAS-BLED score 2.0±1.0 1.9±1.1 0.001
HAS-BLED score ≥3 614 (26.8) 1,033 (26.1) 0.571
Hypertension 1,608 (70.2) 2,632 (66.5) 0.012
Diabetes mellitus 571 (24.9) 1,026 (25.9) 0.351
Myocardial infarction 51 (2.2) 154 (3.9) 0.002
Prior valve surgery 14 (0.6) 10 (0.3) 0.086
Congestive heart failure 254 (11.1) 378 (9.6) 0.147
Peripheral vascular disease 95 (4.1) 233 (5.9) 0.011
Stroke or transient ischemic attack 359 (15.7) 593 (15.0) 0.326
Dyslipidemia 887 (38.7) 1,297 (32.8) <0.001
Pacemaker implant 221 (9.6) 187 (4.7) <0.001
Implantable cardioverter-defibrillator 20 (0.9) 47 (1.2) 0.212
eGFR (mL/min) 76.8±23.7 76.3±20.3 0.375
Chronic kidney disease (eGFR <60 mL/min) 245 (10.7) 376 (9.5) 0.29
Cancer history 193 (8.4) 437 (11.0) 0.003
Any bleeding history 221 (9.6) 361 (9.1) 0.715
LA volume index (mL/m2) 51.4±27.6 45.3±24.5 <0.001
Left ventricular ejection fraction (%) 62.5±14.6 60.3±9.7 <0.001
E/E′ 13.7±6.7 11.1±14.8 <0.001
AF = atrial fibrillation; CHA2DS2-VASc = congestive heart failure, hypertension, age >75, diabetes mellitus, prior stroke or transient ischemic attack, vascular 
disease, age >65, female; E/E′ = early diastolic mitral inflow velocity/mitral annular velocity; eGFR = estimated glomerular filtration rate; EHRA = European 
Heart Rhythm Association; ESRD = end-stage renal disease; HAS-BLED = hypertension, abnormal renal/liver function; serum creatinine ≥2.3 mg/dL or bilirubin 
>2 × upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase >3 × upper limit of normal, stroke, 
bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly; LA = left atrium.
*Excluding points for sex category.
Table 2. Distribution of rhythm and rate control strategies according to gender
Female (n=2,308) Male (n=3,966) p
Any rhythm control attempt 1,244 (54.6) 2,470 (62.7) <0.001
RFCA for AF 285 (12.4) 707 (17.9) <0.001
Electrical cardioversion 282 (12.3) 775 (19.6) <0.001
Antiarrhythmic drug 1,018 (44.7) 1,953 (49.5) <0.001
Amiodarone 198 (8.7) 520 (13.2) <0.001
Dronedarone 62 (2.7) 94 (2.4) 0.461
Propafenone 76 (3.3) 100 (2.5) 0.079
Propafenone SR 258 (11.3) 455 (11.5) 0.833
Flecainide 470 (20.6) 882 (22.3) 0.118
Sotalol 20 (0.9) 50 (1.3) 0.201
Pilsicainide 49 (2.1) 75 (1.9) 0.56
Rate control drug usage
Beta blocker 1,120 (49.1) 1,914 (48.4) 0.639
Calcium channel blocker 664 (29.1) 1,131 (28.6) 0.708
Digitalis 217 (9.5) 218 (5.5) <0.001
AF = atrial fibrillation; RFCA = radiofrequency catheter ablation; SR = sustained release.
Antithrombotic therapy
Oral anticoagulants were prescribed to 69% of the patients overall, including warfarin (17%) 
and NOACs (52%). Oral anticoagulant usage was more frequent in women than men (76.7% 
vs. 64.6%, p<0.001) and warfarin was used more frequently in men than in women (14.9% vs. 
18.9%, p=0.001, Table 3). However, NOACs were prescribed far more frequently for women 
than men (61.8% vs. 45.8%, p<0.001). The use of dabigatran was not significantly different 
between female and male patients. Rivaroxaban, apixaban, and edoxaban were all used more 
frequently in females than males.
Anticoagulation status was next analyzed according to the 2016 European Society of 
Cardiology guideline. Among patients with a CHA2DS2-VA score of 1, the proportion of 
patients taking oral anticoagulation medication was significantly higher in women than men. 
In patients with a CHA2DS2-VA score of 2 or more, the rate of anticoagulation usage was also 
higher in women than men, although the difference was small (85.7% vs. 81.9%, p=0.002, 
Table 3, Figure 1).
In the fall of 2015, the Korean reimbursement guideline changed from using the CHADS2 
score to the CHA2DS2-VASc score. Therefore, we also compared anticoagulation prescription 
patterns for patients with AF according to CHADS2 score. Among patients with a CHADS2 
score of 1, the proportion of females taking oral anticoagulation was significantly higher than 
that of males (74.3% vs. 53.3%, p<0.001). In patients with a CHADS2 ≥2 score of 2 or more, 
the anticoagulation rate was also higher in women than in men (86.1% vs. 81.7%, p=0.001).
NOAC dose relevance was also analyzed according to each manufacturer's recommendation. 
The information about the dose of NOAC was available in 1,409 patients. The guideline-
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Table 3. Comparison of anticoagulation status between males and females
Female (n=2,308) Male (n=3,966) p
Any anticoagulant 1,771 (76.7) 2,564 (64.6) <0.001
Warfarin 344 (14.9) 748 (18.9) <0.001
NOAC 1,427 (61.8) 1,818 (45.8) <0.001
Dabigatran 331 (14.3) 541 (13.6) 0.462
Rivaroxaban 332 (14.4) 439 (11.1) <0.001
Apixaban 561 (24.3) 637 (16.1) <0.001
Edoxaban 204 (8.8) 203 (5.1) <0.001
NOAC dosing adequacy* <0.001
Guideline-recommended dose 515 (36.6) 772 (43.0)
Insufficient dose 867 (61.5) 1,011 (56.3)
Over dose 27 (1.9) 13 (0.7)
Anticoagulation rate for patients with
CHA2DS2-VA score=1† 335 (70.2) 429 (44.1) <0.001
Warfarin 63 (13.2) 197 (20.2) 0.001
NOAC 272 (57.0) 232 (23.8) <0.001
CHA2DS2-VA score=2 or higher† 1,361 (85.7) 1,952 (81.9) 0.002
Warfarin 243 (15.3) 469 (19.7) <0.001
NOAC 1,118 (70.4) 1,485 (62.3) <0.001
CHADS2 score=1 544 (74.3) 684 (53.3) <0.001
CHADS2 score=2 or higher 1,092 (86.1) 1,629 (81.7) 0.001
Antiplatelets
Aspirin 318 (14.6) 828 (21.5) <0.001
Clopidogrel 111 (5.1) 298 (7.7) <0.001
NOAC = non-vitamin K antagonist oral anticoagulant.
*Information about the NOAC dosage was missing in 28 female and 22 male patients; †Excluding points for sex category.
recommended dose was used less often in women than in men (36.6% vs. 43.0%, p<0.001). 
In women, insufficient NOAC dosing (61.5%) and overdosing (1.9%) were more common 
than in men (p<0.001). Men received more aspirin; this finding may be due to the fact that 
history of myocardial infarction and history of coronary disease were more common in men.
DISCUSSION
We found that female patients with AF were treated more conservatively than male patients 
with AF, i.e., the females received less antiarrhythmic drugs, underwent less electric 
cardioversion, and had less radiofrequency catheter ablation.
In patients with a CHA2DS2-VA score of 1, the percentage of female patients taking oral 
anticoagulation medication was significantly higher than that of male patients. While 
insufficient NOAC dosing was common in both sexes, it was significantly more frequent in 
women.
In our data, female subjects were older and had more severe symptoms than males, 
consistent with previous analyses of data from Western countries.3) Analysis of a European 
cohort found that heart failure was more frequent in women, but we found that heart failure 
had the same prevalence across the 2 gender groups (11.1% vs. 9.6%, p=0.147). Female 
gender is a risk factor of stroke based on many analyses of Western cohorts.9)10)18) However, 
it is controversial whether this is also true in Asian populations. Recent reports of Asian 
populations have suggested that female sex might not be a risk factor for stroke in patients 
with AF.19-22) Consistent with this finding, we found that the proportions of patients with 
previous stroke were not significantly different between men and women, even though 
women were older and had more frequent hypertension. Our results, along with analysis 
of a cohort in Japan, suggest that female gender is not so strongly related to stroke in Asian 
populations with AF.
Despite experiencing more severe symptoms, women were less likely to receive rhythm 
control treatment than men. In the Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation (ORBIT-AF) study, the use of antiarrhythmic drug therapy was similar in 
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Figure 1. Proportions of anticoagulation use in men and women according to stroke risk scores (Low stroke-risk group=CHA2DS2-VA score of 1, intermediate to 
high stroke-risk group= CHA2DS2-VA score of 2 or more). 
NOAC = non-vitamin K antagonist oral anticoagulant. 
*p<0.01; †p<0.001.
men and women. However, women were less likely to undergo electric cardioversion and 
radiofrequency catheter ablation.6)
In the EURObservational Research Programme Atrial Fibrillation (EORP-AF) registry, women 
with symptomatic AF were more likely to receive rate control therapy alone than men.3) In 
this European registry, women were less likely to receive both electric cardioversion and 
pharmacological conversion, but catheter ablation was performed on similar percentages of 
males and females.
Our data are generally consistent with previous reports. We found that women received 
all 3 kinds of rhythm control strategies less frequently than men. Women had more severe 
symptoms than men and rhythm control therapy was used inadequately in women. These 
conclusions are shared by almost all previous reports.1-4)6) One potential explanation for this 
finding is the lower economic status of women in Korea. According to previous articles, 
gender wage gaps are still exist in Korea.23) Married women have relatively low employment 
rates in Korea. In addition, women are still under-employed in managerial and professional 
positions and more commonly employed in irregular jobs with lower levels of wage and job 
security.23)24) Therefore, expensive procedures were performed more frequently in men.
In the Practice INNovation And CLinical Excellence (PINNACLE) registry, women with 
moderate-to-high risk of stroke were more likely to receive aspirin therapy than oral 
anticoagulants compared to men.25) Furthermore, in a survey of general practitioners in the 
United Kingdom, women with AF and at moderate-to-high risk of stroke were significantly 
less likely to receive oral anticoagulant therapy than men (47% vs. 52%, p=0.006).5) However, 
more recent studies reported that the anticoagulation rate did not differ by gender.6)26) This 
discrepancy may reflect differences in general physician/private care vs. cardiology/academic 
care. Specifically, cardiology specialist care is associated with higher anticoagulation rates 
and better guideline adherence in stroke prevention in AF.27)28)
In the ORBIT-AF II and GARFIELD studies, gender was not a significant predictor of NOAC 
use.26)28) In our analysis, NOACs were used more frequently in women. Particularly in patients 
with a CHA2DS2-VA score of 1, more females than males were taking oral anticoagulation 
medication (70.2% vs. 44.1%, p<0.001, Figure 1). This difference was driven by the more 
frequent NOAC use in female patients with a CHA2DS2-VA score of 1 (overall NOAC 57.0% vs. 
23.8%, p<0.001; dabigatran 12.8% vs. 8.7%, p=0.021; rivaroxaban 13.0% vs 5.9%, p<0.001; 
apixaban 20.8% vs. 6.3%, p<0.001; edoxaban 10.5% vs. 3.0%, p<0.001). This result is a 
consequence of the National Health Insurance policy in Korea. Specifically, Korea's national 
insurance reimbursement policy for NOAC use is based on the CHA2DS2-VASc score. A 
CHA2DS2-VASc score of 2 or more is required for national insurance in Korea to cover the cost 
of NOAC treatment; therefore, women with one additional risk factor can receive NOACs, but 
men with one risk factor cannot be reimbursed for NOAC use. This may explain why warfarin 
use is more frequent in men than in women.
In our registry, NOACs were used more frequently in women; however, insufficient dosing 
was also much higher in females. In the real world, insufficient dosing is a common issue. A 
population-based cohort study of patients from the province of Quebec reported that women 
with AF were more likely to be treated with a lower dose of dabigatran than men.29) An 
important conclusion is that adequate dosage should be advocated in Korea.
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This was a cross-sectional study; therefore, we could not assess the impact of gender 
differences over time. Follow-up data will be analyzed in a future study. Furthermore, the 
study population size may be too small to have sufficient statistical power to assess individual 
NOAC differences in distribution. As the female subjects were older and had higher risk, 
these differences may have affected some of the observed differences in our modestly sized 
cohort. We did not have data on anticoagulation control quality, such as drug compliance 
or time in therapeutic range (TTR) data. Moreover, we could not determine how much 
treatment differences between men and women were influenced by patient preference 
as opposed to baseline differences and/or physician bias. Although our data have several 
limitations, few studies have used large data sets from an Asian population to investigate 
gender differences in AF. Our study provides important data for analyzing differences in 
healthcare utilization between men and women in Asia.
In conclusion, in Korea, female patients with AF were treated more conservatively than male 
patients with AF. Specifically, the female patients were prescribed antiarrhythmic drugs less 
frequently, underwent electric cardioversion less frequently, and had radiofrequency catheter 
ablation less frequently than the male patients. Female patients received NOACs more 
frequently than male patients. While insufficient NOAC dosing was common in both sexes, it 
was significantly more frequent in women. Further studies are needed to determine whether 
these differences have clinically meaningful impact.
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